Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Immune cell gene signatures for profiling the microenvironment of solid tumors.

Nirmal AJ, Regan T, Shih BB, Hume DA, Sims AH, Freeman TC.

Cancer Immunol Res. 2018 Sep 28. pii: canimm.0342.2018. doi: 10.1158/2326-6066.CIR-18-0342. [Epub ahead of print]

PMID:
30266715
2.

Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.

Baxter DE, Kim B, Hanby AM, Verghese ET, Sims AH, Hughes TA.

Clin Breast Cancer. 2018 Jul 6. pii: S1526-8209(18)30447-6. doi: 10.1016/j.clbc.2018.07.002. [Epub ahead of print]

PMID:
30055962
3.

Regulation of breast cancer induced bone disease by cancer-specific IKKβ.

Marino S, Bishop RT, Capulli M, Sophocleous A, Logan JG, Mollat P, Mognetti B, Ventura L, Sims AH, Rucci N, Ralston SH, Idris AI.

Oncotarget. 2018 Mar 23;9(22):16134-16148. doi: 10.18632/oncotarget.24743. eCollection 2018 Mar 23.

4.

Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer.

Ward E, Varešlija D, Charmsaz S, Fagan A, Browne AL, Cosgrove N, Cocchiglia S, Purcell SP, Hudson L, Das S, O'Connor D, O'Halloran PJ, Sims AH, Hill AD, Young LS.

Clin Cancer Res. 2018 Aug 1;24(15):3692-3703. doi: 10.1158/1078-0432.CCR-17-2615. Epub 2018 Mar 22.

PMID:
29567811
5.

MCL-1 is a prognostic indicator and drug target in breast cancer.

Campbell KJ, Dhayade S, Ferrari N, Sims AH, Johnson E, Mason SM, Dickson A, Ryan KM, Kalna G, Edwards J, Tait SWG, Blyth K.

Cell Death Dis. 2018 Jan 16;9(2):19. doi: 10.1038/s41419-017-0035-2.

6.

Kindlin-1 Promotes Pulmonary Breast Cancer Metastasis.

Sarvi S, Patel H, Li J, Dodd GL, Creedon H, Muir M, Ward J, Dawson JC, Lee M, Culley J, Salter DM, Sims AH, Byron A, Brunton VG.

Cancer Res. 2018 Mar 15;78(6):1484-1496. doi: 10.1158/0008-5472.CAN-17-1518. Epub 2018 Jan 12.

7.

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.

Hollis RL, Meynert AM, Churchman M, Rye T, Mackean M, Nussey F, Arends MJ, Sims AH, Semple CA, Herrington CS, Gourley C.

BMC Cancer. 2018 Jan 3;18(1):16. doi: 10.1186/s12885-017-3981-2.

8.

GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment.

De Francesco EM, Sims AH, Maggiolini M, Sotgia F, Lisanti MP, Clarke RB.

Breast Cancer Res. 2017 Dec 6;19(1):129. doi: 10.1186/s13058-017-0923-5.

9.

Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth.

Canel M, Byron A, Sims AH, Cartier J, Patel H, Frame MC, Brunton VG, Serrels B, Serrels A.

Cancer Res. 2017 Oct 1;77(19):5301-5312. doi: 10.1158/0008-5472.CAN-17-0418. Epub 2017 Aug 14.

10.

Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast.

Martínez-Pérez C, Turnbull AK, Ekatah GE, Arthur LM, Sims AH, Thomas JS, Dixon JM.

Cancer Treat Rev. 2017 Apr;55:163-172. doi: 10.1016/j.ctrv.2017.03.009. Epub 2017 Mar 31. Review.

PMID:
28402908
11.

WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel.

Artibani M, Sims AH, Slight J, Aitken S, Thornburn A, Muir M, Brunton VG, Del-Pozo J, Morrison LR, Katz E, Hastie ND, Hohenstein P.

Sci Rep. 2017 Mar 27;7:45255. doi: 10.1038/srep45255.

12.
13.

Differential expression of store-operated calcium- and proliferation-related genes in hepatocellular carcinoma cells following TRPC1 ion channel silencing.

Selli C, Pearce DA, Sims AH, Tosun M.

Mol Cell Biochem. 2016 Sep;420(1-2):129-40. doi: 10.1007/s11010-016-2776-0. Epub 2016 Jul 22.

14.

Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies.

Pearce DA, Arthur LM, Turnbull AK, Renshaw L, Sabine VS, Thomas JS, Bartlett JM, Dixon JM, Sims AH.

Sci Rep. 2016 Jul 7;6:29434. doi: 10.1038/srep29434.

15.

Intermittent energy restriction induces changes in breast gene expression and systemic metabolism.

Harvie MN, Sims AH, Pegington M, Spence K, Mitchell A, Vaughan AA, Allwood JW, Xu Y, Rattray NJ, Goodacre R, Evans DG, Mitchell E, McMullen D, Clarke RB, Howell A.

Breast Cancer Res. 2016 May 28;18(1):57. doi: 10.1186/s13058-016-0714-4.

16.

Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.

Creedon H, Gómez-Cuadrado L, Tarnauskaitė Ž, Balla J, Canel M, MacLeod KG, Serrels B, Fraser C, Unciti-Broceta A, Tracey N, Le Bihan T, Klinowska T, Sims AH, Byron A, Brunton VG.

Oncotarget. 2016 Mar 8;7(10):11539-52. doi: 10.18632/oncotarget.7317.

17.

Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.

Varešlija D, McBryan J, Fagan A, Redmond AM, Hao Y, Sims AH, Turnbull A, Dixon JM, Ó Gaora P, Hudson L, Purcell S, Hill AD, Young LS.

Clin Cancer Res. 2016 Jun 1;22(11):2765-77. doi: 10.1158/1078-0432.CCR-15-1583. Epub 2016 Jan 13.

18.

Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.

Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, Gómez-Cuadrado L, Canel M, Muir M, Ring JE, Maniati E, Sims AH, Pachter JA, Brunton VG, Gilbert N, Anderton SM, Nibbs RJ, Frame MC.

Cell. 2015 Sep 24;163(1):160-73. doi: 10.1016/j.cell.2015.09.001.

19.

Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.

Simões BM, O'Brien CS, Eyre R, Silva A, Yu L, Sarmiento-Castro A, Alférez DG, Spence K, Santiago-Gómez A, Chemi F, Acar A, Gandhi A, Howell A, Brennan K, Rydén L, Catalano S, Andó S, Gee J, Ucar A, Sims AH, Marangoni E, Farnie G, Landberg G, Howell SJ, Clarke RB.

Cell Rep. 2015 Sep 29;12(12):1968-77. doi: 10.1016/j.celrep.2015.08.050. Epub 2015 Sep 17.

20.

MEG3 long noncoding RNA regulates the TGF-β pathway genes through formation of RNA-DNA triplex structures.

Mondal T, Subhash S, Vaid R, Enroth S, Uday S, Reinius B, Mitra S, Mohammed A, James AR, Hoberg E, Moustakas A, Gyllensten U, Jones SJ, Gustafsson CM, Sims AH, Westerlund F, Gorab E, Kanduri C.

Nat Commun. 2015 Jul 24;6:7743. doi: 10.1038/ncomms8743.

21.

Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.

Turnbull AK, Arthur LM, Renshaw L, Larionov AA, Kay C, Dunbier AK, Thomas JS, Dowsett M, Sims AH, Dixon JM.

J Clin Oncol. 2015 Jul 10;33(20):2270-8. doi: 10.1200/JCO.2014.57.8963. Epub 2015 Jun 1.

PMID:
26033813
22.

Monocytes and macrophages, implications for breast cancer migration and stem cell-like activity and treatment.

Ward R, Sims AH, Lee A, Lo C, Wynne L, Yusuf H, Gregson H, Lisanti MP, Sotgia F, Landberg G, Lamb R.

Oncotarget. 2015 Jun 10;6(16):14687-99.

23.

Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.

Busch S, Sims AH, Stål O, Fernö M, Landberg G.

Cancer Res. 2015 Apr 1;75(7):1457-69. doi: 10.1158/0008-5472.CAN-14-1583.

24.

Gene expression profiling reveals biological pathways responsible for phenotypic heterogeneity between UK and Sri Lankan oral squamous cell carcinomas.

Saeed AA, Sims AH, Prime SS, Paterson I, Murray PG, Lopes VR.

Oral Oncol. 2015 Mar;51(3):237-46. doi: 10.1016/j.oraloncology.2014.12.004. Epub 2015 Jan 2.

PMID:
25560800
25.

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.

Arthur LM, Turnbull AK, Renshaw L, Keys J, Thomas JS, Wilson TR, Lackner MR, Sims AH, Dixon JM.

Breast Cancer Res Treat. 2014 Aug;147(1):211-9. doi: 10.1007/s10549-014-3080-x. Epub 2014 Aug 9.

PMID:
25104442
26.

Molecular changes in lobular breast cancers in response to endocrine therapy.

Arthur LM, Turnbull AK, Webber VL, Larionov AA, Renshaw L, Kay C, Thomas JS, Dixon JM, Sims AH.

Cancer Res. 2014 Oct 1;74(19):5371-6. doi: 10.1158/0008-5472.CAN-14-0620. Epub 2014 Aug 6.

27.

Increased STAT1 signaling in endocrine-resistant breast cancer.

Huang R, Faratian D, Sims AH, Wilson D, Thomas JS, Harrison DJ, Langdon SP.

PLoS One. 2014 Apr 11;9(4):e94226. doi: 10.1371/journal.pone.0094226. eCollection 2014.

28.

Engineering a synthetic cell panel to identify signalling components reprogrammed by the cell growth regulator anterior gradient-2.

Gray TA, Alsamman K, Murray E, Sims AH, Hupp TR.

Mol Biosyst. 2014 Jun;10(6):1409-25. doi: 10.1039/c4mb00113c. Epub 2014 Apr 7.

PMID:
24710632
29.

A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity.

Ablett MP, O'Brien CS, Sims AH, Farnie G, Clarke RB.

Oncotarget. 2014 Feb 15;5(3):599-612.

30.

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.

Lehn S, Tobin NP, Sims AH, Stål O, Jirström K, Axelson H, Landberg G.

BMC Cancer. 2014 Feb 22;14:119. doi: 10.1186/1471-2407-14-119.

31.

Modulation of strain-specific differences in gene expression by cannabinoid type 2 receptor deficiency.

Sophocleous A, Sims AH, Idris AI, Ralston SH.

Calcif Tissue Int. 2014 Apr;94(4):423-32. doi: 10.1007/s00223-013-9823-6. Epub 2013 Dec 27.

PMID:
24370613
32.

Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: A role for PIP4K2B in the regulation of E-cadherin expression.

Keune WJ, Sims AH, Jones DR, Bultsma Y, Lynch JT, Jirström K, Landberg G, Divecha N.

Cancer Res. 2013 Dec 1;73(23):6913-25. doi: 10.1158/0008-5472.CAN-13-0424. Epub 2013 Oct 14.

33.

Use of microarray analysis to investigate EMT gene signatures.

Sims AH, Larionov AA, Harrison DJ, Katz E.

Methods Mol Biol. 2013;1046:85-95. doi: 10.1007/978-1-62703-538-5_5.

PMID:
23868583
34.

Wnt pathway activity in breast cancer sub-types and stem-like cells.

Lamb R, Ablett MP, Spence K, Landberg G, Sims AH, Clarke RB.

PLoS One. 2013 Jul 4;8(7):e67811. doi: 10.1371/journal.pone.0067811. Print 2013.

35.

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.

Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart MJ, Sotiriou C.

PLoS One. 2013;8(1):e53292. doi: 10.1371/journal.pone.0053292. Epub 2013 Jan 2.

36.

Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation.

Meyer C, Sims AH, Morgan K, Harrison B, Muir M, Bai J, Faratian D, Millar RP, Langdon SP.

Endocr Relat Cancer. 2013 Feb 18;20(1):123-36. doi: 10.1530/ERC-12-0192. Print 2013 Feb.

37.

Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns.

Sproul D, Kitchen RR, Nestor CE, Dixon JM, Sims AH, Harrison DJ, Ramsahoye BH, Meehan RR.

Genome Biol. 2012 Oct 3;13(10):R84. doi: 10.1186/gb-2012-13-10-r84.

38.

Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.

Hu H, Goltsov A, Bown JL, Sims AH, Langdon SP, Harrison DJ, Faratian D.

Cell Signal. 2013 Jan;25(1):26-32. doi: 10.1016/j.cellsig.2012.09.014. Epub 2012 Sep 18.

PMID:
23000339
39.

Direct integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis.

Turnbull AK, Kitchen RR, Larionov AA, Renshaw L, Dixon JM, Sims AH.

BMC Med Genomics. 2012 Aug 21;5:35. doi: 10.1186/1755-8794-5-35.

40.

The T box transcription factor TBX2 promotes epithelial-mesenchymal transition and invasion of normal and malignant breast epithelial cells.

Wang B, Lindley LE, Fernandez-Vega V, Rieger ME, Sims AH, Briegel KJ.

PLoS One. 2012;7(7):e41355. doi: 10.1371/journal.pone.0041355. Epub 2012 Jul 23.

41.

Targeting of Rac GTPases blocks the spread of intact human breast cancer.

Katz E, Sims AH, Sproul D, Caldwell H, Dixon MJ, Meehan RR, Harrison DJ.

Oncotarget. 2012 Jun;3(6):608-19.

42.

KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.

Moleirinho S, Chang N, Sims AH, Tilston-Lünel AM, Angus L, Steele A, Boswell V, Barnett SC, Ormandy C, Faratian D, Gunn-Moore FJ, Reynolds PA.

Oncogene. 2013 Apr 4;32(14):1821-30. doi: 10.1038/onc.2012.196. Epub 2012 May 21.

PMID:
22614006
43.

FRMD4A upregulation in human squamous cell carcinoma promotes tumor growth and metastasis and is associated with poor prognosis.

Goldie SJ, Mulder KW, Tan DW, Lyons SK, Sims AH, Watt FM.

Cancer Res. 2012 Jul 1;72(13):3424-36. doi: 10.1158/0008-5472.CAN-12-0423. Epub 2012 May 7.

44.

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.

Sims AH, Zweemer AJ, Nagumo Y, Faratian D, Muir M, Dodds M, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP.

Br J Cancer. 2012 May 22;106(11):1779-89. doi: 10.1038/bjc.2012.176. Epub 2012 May 1.

45.

Relative impact of key sources of systematic noise in Affymetrix and Illumina gene-expression microarray experiments.

Kitchen RR, Sabine VS, Simen AA, Dixon JM, Bartlett JM, Sims AH.

BMC Genomics. 2011 Dec 1;12:589. doi: 10.1186/1471-2164-12-589.

46.

GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines.

Morgan K, Meyer C, Miller N, Sims AH, Cagnan I, Faratian D, Harrison DJ, Millar RP, Langdon SP.

BMC Cancer. 2011 Nov 3;11:476. doi: 10.1186/1471-2407-11-476.

47.

Cyclin D1, Id1 and EMT in breast cancer.

Tobin NP, Sims AH, Lundgren KL, Lehn S, Landberg G.

BMC Cancer. 2011 Sep 28;11:417. doi: 10.1186/1471-2407-11-417.

48.

Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy.

Faratian D, Sims AH, Mullen P, Kay C, Um I, Langdon SP, Harrison DJ.

PLoS One. 2011;6(8):e23772. doi: 10.1371/journal.pone.0023772. Epub 2011 Aug 31.

49.

Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.

Lawrenson K, Sproul D, Grun B, Notaridou M, Benjamin E, Jacobs IJ, Dafou D, Sims AH, Gayther SA.

Carcinogenesis. 2011 Oct;32(10):1540-9. doi: 10.1093/carcin/bgr140. Epub 2011 Aug 22.

PMID:
21859834
50.

Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.

Faratian D, Zweemer AJ, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP.

Clin Cancer Res. 2011 Jul 1;17(13):4451-61. doi: 10.1158/1078-0432.CCR-10-2461. Epub 2011 May 13.

Supplemental Content

Support Center